ARCHIVES

Phase II Study Of Pfizer Drug Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 32 No. 4 | April 24, 2009

Download PDF Visit The Full Archive

Related Articles

In Brief: DCT Board Rejects Move to Count Individual P01 Projects Toward The NIH Total Of 5,000 Grants

June 24, 1983

Tafinlar Subgroup Data Shows Median OS of 20 Months

October 31, 2014

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012

Clinical Research: Cooperative Groups Form Coalition to Advance Trials

November 14, 1997

In Brief: David Tweardy named head of internal medicine at MD Anderson

September 19, 2014

Solomon Garb’s Questions/Answers

January 9, 1981